Top Markets
Coin of the day
Theseus Pharmaceuticals, Inc. Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc.

THRX
Rang in Aktien #19949
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on... Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer. All their research and development efforts aim to overcome drug resistance mutations within key driver oncogenes, which are mutated genes that promote cancer. Founded in 2017, the company operates out of Cambridge, Massachusetts.
Aktienkurs
$4.06
Zuletzt synchronisiert: 2024-02-23
Marktkapitalisierung
$145.61M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Theseus Pharmaceuticals, Inc. (THRX)

Kategorie

Kursverlauf für Theseus Pharmaceuticals, Inc. (THRX)
Höchster Schlusskurs: $4.07 am 2024-02-01

Niedrigster Schlusskurs: $16.20 am 2021-10-01
Kursverlauf der Aktie von Theseus Pharmaceuticals, Inc. von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2024 5.46%
2023 -30.80%
2022 -54.19%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$553.09 42.20%
US
$1.02K 50.56%
NL
$158.64 525.80%
US
$122.47 -12.71%
AU
$772.27 8.67%
CH